| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Faisal Alibhai | Q57000874 |
| P2093 | author name string | Tami A Martino | |
| Elena V Tsimakouridze | |||
| P2860 | cites work | Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients | Q50122132 |
| Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. | Q50596876 | ||
| Excerpts from the United States Renal Data System 2006 Annual Data Report. | Q50795168 | ||
| Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. | Q51205732 | ||
| CircadiOmics: integrating circadian genomics, transcriptomics, proteomics and metabolomics. | Q51338724 | ||
| Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity. | Q51524886 | ||
| Genetic components of the circadian clock regulate thrombogenesis in vivo. | Q52586378 | ||
| Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality | Q57085545 | ||
| Rhythmic histone acetylation underlies transcription in the mammalian circadian clock | Q59072611 | ||
| The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction | Q60164685 | ||
| Can an angiotensin-converting enzyme inhibitor with a short half-life effectively lower blood pressure for 24 hours? | Q68109352 | ||
| Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects | Q68345878 | ||
| Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1) | Q69173266 | ||
| Cardiovascular effects, pharmacokinetics, and converting enzyme inhibition of enalapril after morning versus evening administration | Q70470448 | ||
| Mechanisms underlying the morning increase in platelet aggregation: a flow cytometry study | Q71879923 | ||
| Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators | Q72232746 | ||
| Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men | Q73318670 | ||
| Management of antihypertensive treatment with Lisinopril: a chronotherapeutic approach | Q73653282 | ||
| Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study | Q78456802 | ||
| Circadian variation of the efficacy of thrombolytic therapy in acute myocardial infarction-isn't the time ripe for cardiovascular chronotherapy? | Q80117056 | ||
| Thrombomodulin is a clock-controlled gene in vascular endothelial cells | Q81234456 | ||
| Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Counc | Q81783576 | ||
| Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction | Q83157171 | ||
| Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association | Q22241921 | ||
| Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2 | Q24301552 | ||
| The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control | Q24597971 | ||
| Obesity and metabolic syndrome in circadian Clock mutant mice | Q24627935 | ||
| Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists | Q24629345 | ||
| New frontiers in obstructive sleep apnoea | Q26823972 | ||
| Sleep apnea and cardiovascular risk | Q26861719 | ||
| Circadian clock control of endocrine factors | Q27022325 | ||
| Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients | Q28191955 | ||
| Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 | ||
| Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes | Q28290094 | ||
| Human blood metabolite timetable indicates internal body time | Q28388632 | ||
| Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology | Q28512844 | ||
| The histone methyltransferase MLL1 permits the oscillation of circadian gene expression | Q28594155 | ||
| Extensive and divergent circadian gene expression in liver and heart | Q29615206 | ||
| Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study | Q29615583 | ||
| Central and peripheral circadian clocks in mammals | Q29616556 | ||
| A clockwork web: circadian timing in brain and periphery, in health and disease | Q29618069 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour | Q30657215 | ||
| Diurnal protein expression in blood revealed by high throughput mass spectrometry proteomics and implications for translational medicine and body time of day. | Q33286982 | ||
| In search of ideal hemodialysis: is prolonged frequent dialysis the answer? | Q33749215 | ||
| Circadian clocks and vascular function | Q33765425 | ||
| The day/night proteome in the murine heart | Q33913001 | ||
| Biomarkers in acute cardiac disease: the present and the future | Q33997300 | ||
| The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors | Q34023650 | ||
| Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis | Q34129990 | ||
| Day/night rhythms in gene expression of the normal murine heart | Q34301391 | ||
| Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy | Q34357433 | ||
| Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial | Q34366640 | ||
| REV-ERB and ROR nuclear receptors as drug targets. | Q34407313 | ||
| A circadian gene expression atlas in mammals: implications for biology and medicine | Q34445166 | ||
| Nocturnal hemodialysis: three-year experience. | Q34468753 | ||
| Small molecule modifiers of circadian clocks. | Q34480532 | ||
| Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). | Q34539439 | ||
| Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators | Q34539986 | ||
| Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. | Q34652165 | ||
| Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial | Q34690053 | ||
| A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group | Q34718800 | ||
| Obstructive sleep apnoea and its cardiovascular consequences | Q34909223 | ||
| Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period | Q34982171 | ||
| Sleep apnea and heart failure: Part I: obstructive sleep apnea | Q35095882 | ||
| Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact | Q35112353 | ||
| Chromatin landscape and circadian dynamics: Spatial and temporal organization of clock transcription | Q35699594 | ||
| The human circadian metabolome. | Q35786923 | ||
| Coordination of the transcriptome and metabolome by the circadian clock | Q35887331 | ||
| Circadian clocks - the fall and rise of physiology | Q36337962 | ||
| The circadian clock within the heart: potential influence on myocardial gene expression, metabolism, and function | Q36350915 | ||
| Cardiac biomarkers: a contemporary status report | Q36359877 | ||
| Circadian oscillations of protein-coding and regulatory RNAs in a highly dynamic mammalian liver epigenome | Q36523534 | ||
| Pharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1 | Q36653623 | ||
| Molecular circadian rhythms in central and peripheral clocks in mammals. | Q36799431 | ||
| Molecular clocks in pharmacology | Q36934962 | ||
| Chronobiology, drug delivery, and chronotherapeutics | Q36947532 | ||
| Biological rhythms in the absorption, distribution, metabolism and excretion of drugs | Q37021248 | ||
| Diurnal variations in myocardial metabolism | Q37096383 | ||
| Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients | Q37113917 | ||
| Obesity in mice with adipocyte-specific deletion of clock component Arntl. | Q37195570 | ||
| Measurement of internal body time by blood metabolomics. | Q37209677 | ||
| Molecular-timetable methods for detection of body time and rhythm disorders from single-time-point genome-wide expression profiles | Q37388348 | ||
| Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep/wake cycle | Q37512114 | ||
| Diurnal physiology: core principles with application to the pathogenesis, diagnosis, prevention, and treatment of myocardial hypertrophy and failure | Q37531583 | ||
| Molecular time: an often overlooked dimension to cardiovascular disease | Q37635623 | ||
| The role of clock genes in pharmacology | Q37670214 | ||
| Concepts of circadian chronopharmacology | Q37672716 | ||
| The cardiomyocyte circadian clock: emerging roles in health and disease | Q37702694 | ||
| A novel mechanism controlling resetting speed of the circadian clock to environmental stimuli | Q37706325 | ||
| Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications | Q37826498 | ||
| The rhythm of the normal human heart | Q39471438 | ||
| Biologic rhythms and medicine | Q39512589 | ||
| Circadian variation of blood-pressure | Q39539239 | ||
| Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea | Q39645233 | ||
| Arousal and the Circadian Rhythm of Blood Pressure | Q40570744 | ||
| Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians | Q41205463 | ||
| Circadian variation in the frequency of sudden cardiac death | Q41477518 | ||
| Circadian variation in the frequency of onset of acute myocardial infarction | Q41781518 | ||
| Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension | Q41943327 | ||
| Impact of frequent nocturnal hemodialysis on myocardial mechanics and cardiomyocyte gene expression | Q42507226 | ||
| The Bedtime Administration Ameliorates Blood Pressure Variability and Reduces Urinary Albumin Excretion in Amlodipine-Olmesartan Combination Therapy | Q42674666 | ||
| Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing | Q42960996 | ||
| Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension | Q43044200 | ||
| Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS) | Q43627944 | ||
| Short-Term Blood Pressure, Noradrenergic, and Vascular Effects of Nocturnal Home Hemodialysis | Q44616356 | ||
| Circadian influence on effect of propranolol on exercise-induced tachycardia in healthy subjects | Q44814729 | ||
| Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol | Q44900702 | ||
| Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. | Q46015855 | ||
| Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients | Q46163937 | ||
| Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension | Q46589353 | ||
| Treatment of non-dipper hypertension with bedtime administration of valsartan | Q46691728 | ||
| Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome | Q47782450 | ||
| Clock genes display rhythmic expression in human hearts | Q47793725 | ||
| Glucocorticoids entrain molecular clock components in human peripheral cells | Q48008388 | ||
| Chronomics of pressure overload-induced cardiac hypertrophy in mice reveals altered day/night gene expression and biomarkers of heart disease | Q48231955 | ||
| Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing | Q48289407 | ||
| The primary benefits of angiotensin-converting enzyme inhibition on cardiac remodeling occur during sleep time in murine pressure overload hypertrophy | Q48303456 | ||
| Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the rat. | Q48477399 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circadian rhythm | Q208353 |
| circulatory system | Q11068 | ||
| P304 | page(s) | 77 | |
| P577 | publication date | 2015-04-17 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Therapeutic applications of circadian rhythms for the cardiovascular system | |
| P478 | volume | 6 |
| Q90609548 | "Photobiomics": Can Light, Including Photobiomodulation, Alter the Microbiome? |
| Q48132649 | Altered Circadian Timing System-Mediated Non-Dipping Pattern of Blood Pressure and Associated Cardiovascular Disorders in Metabolic and Kidney Diseases |
| Q57826207 | Chronic Heart Failure Abolishes Circadian Rhythms in Resting and Chemoreflex Breathing |
| Q64229950 | Chronic chemotherapy with paclitaxel nanoparticles induced apoptosis in lung cancer in vitro and in vivo |
| Q28082902 | Circadian molecular clock in lung pathophysiology |
| Q91845071 | Circadian rhythms and the molecular clock in cardiovascular biology and disease |
| Q92437973 | Complexities in cardiovascular rhythmicity: perspectives on circadian normality, ageing and disease |
| Q39138693 | Concise Review: Increasing the Validity of Cerebrovascular Disease Models and Experimental Methods for Translational Stem Cell Research |
| Q51793703 | Development and Therapeutic Potential of Small-Molecule Modulators of Circadian Systems. |
| Q51701324 | Diurnal Variation of the Peripheral Cholinergic Antiinflammatory Function in Mice. |
| Q41854523 | Editorial: Therapeutic implications of circadian rhythms |
| Q92718408 | Insufficient exercise intensity for clinical benefit? Monitoring and quantification of a community-based Phase III cardiac rehabilitation programme: A United Kingdom perspective |
| Q64068052 | The Clock Mechanism Influences Neurobiology and Adaptations to Heart Failure in Clock Mice With Implications for Circadian Medicine |
| Q64940215 | Time-restricted feeding restores muscle function in Drosophila models of obesity and circadian-rhythm disruption. |
| Q28395767 | Work Stress and Metabolic Syndrome in Police Officers. A Prospective Study |
Search more.